Findings identify coordinated suppression of a FOXM1-associated MCPH program as part of the GBM radiation response, while suggesting that the radiosensitizing effects of pharmacological FOXM1inhibition extend beyond this transcriptional axis.
Abstract
Glioblastoma (GBM) is characterized by marked heterogeneity, glioma stem-like cells (GSCs), and resistance to therapy. Because GSCs share features with neural progenitor cells (NPCs), we investigated whether neurodevelopmental programs contribute to their response to irradiation. Transcriptional profiling of four patient-derived GSC lines revealed cell line-specific responses, with radiosensitivity correlating with the magnitude of p53 activation and basal expression of its negative regulator, MDM2. Despite this heterogeneity, radiation consistently activated p53-dependent pathways and suppressed cell-cycle programs. Among these, genes associated with primary hereditary microcephaly (MCPH) that regulate NPC proliferation were coordinately repressed. Single-cell RNA sequencing localized this response to G2/M-cycling cells. FOXM1 was similarly reduced following irradiation, emerged as a candidate regulator of a subset of MCPH genes, and correlated with their expression in GBM tumors. Pharmacological inhibition of FOXM1 reduced expression of selected MCPH genes and enhanced radiosensitivity in U251 cells. Together, these findings identify coordinated suppression of a FOXM1-associated MCPH program as part of the GBM radiation response, while suggesting that the radiosensitizing effects of pharmacological FOXM1inhibition extend beyond this transcriptional axis.
An epigenetic drug screen under low-dose irradiation is performed to identify modifiers of radiotherapy response in glioblastoma and identifies BRD9 inhibition as a priming strategy that selectively enhances irradiation-induced lethality without inducing substantial cytotoxicity under baseline conditions.
Nareg Degirmenci, S. A. Celikkol, B. N. Koseoglu et al.· bioRxiv· 0 citations
Glioblastoma (GBM) remains a highly lethal brain tumor with limited therapeutic options and pervasive resistance to standard treatments. Cyclin-dependent kinases (CDKs), key regulators of cell cycle progression and transcription, are frequently dysregulated in GBM and contribute to tumor pathogenesis. We employed a ran...
P. Kaps, A. Hieltscher, Andrea Auditore et al.· Cell Communication and Signa...· 0 citations
This is the first comprehensive study that redefines chemoresistance as a proliferative, MYC-driven state and uncover SRM as a tractable vulnerability, offering new avenues for therapeutic intervention across diverse epithelial malignancies.
Mohammed M. A. Inayatullah, Engin Demirdizen, Z. Keepers et al.· Genome Medicine· 0 citations
A small molecule inhibitor is repurposed to interfere with its binding to DNA, restrict chromatin accessibility at promoters, and constrain tumor growth both in vitro and in vivo to show how increased HMGB2 availability represents a transcriptional addiction that fuels cell-cycle progression and growth.
Adi Danieli-Mackay, Ioanna Papadionysiou, Markos Tsitsianopoulos et al.· Cell Reports· 0 citations
A framework for understanding how early-established genomic backbones and regional transcriptional plasticity jointly drive phenotypic diversity is provided for understanding how genomic diversification intersects with transcriptional plasticity remains incompletely understood.
Serafiina Ohlsbom, S. Mäntylä, R. Nätkin et al.· bioRxiv· 0 citations
Abstract Glioblastoma (GBM) is an aggressive brain tumor characterized by therapy resistance and recurrence. GBM stem cells (GSC) are key drivers of tumor maintenance, therapeutic resistance, and relapse, but targeting them remains clinically elusive due to their overlap with normal neural stem cells (NSC) and a lack o...
Benjamin A. Brakel, D. McKenna, Anish Puri et al.· Cancer Research Communicatio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.